… of 92 patients with all types of thyroid cancer; a progression-free … of chemotherapy in patients
with thyroid cancer is limited to … who are not candidates for other local or systemic therapies. …

… therapy with suppression of serum TSH is a primary therapy in all patients with advanced
differentiated thyroid cancer, and this therapy … is also an important systemic therapy for those …

… targeted therapeutic drugs in clinical research, and explore potentially novel molecular
therapeutic … tyrosine kinase inhibitors approved for systemic therapy for TC, including lenvatinib, …

… Tyrosine kinase inhibitors like vandetanib, sorafenib and lenvatinib are a relatively new
approach to systemic therapy in these cases. Tyrosine kinase receptors, the target structure of …

… that is also derived from epithelial thyroid cells. It accounts for less than 2% of thyroid cancers
but is … Currently, there are no systemic therapeutic strategies of proven benefit in terms of …

… Systemic therapeutic options are limited for medullary thyroid cancer, but several
therapeutic targets show promise for the development of new therapies in the future. …

… were offered aggressive palliation, including stereotactic body RT of lung metastases, as
well as systemic therapies per patient election regardless of initial election of PI or MMT. …

… Anaplastic thyroid carcinoma (ATC) is a highly aggressive form of thyroid cancer, with a
reported median survival rate of only 4 months. While multimodal therapy is frequently advocated…

… In patients with advanced thyroid cancer in need of systemic therapy, molecular testing is
indicated in most cases to detect actionable mutations and identify optimal treatment options …

… thyroid cancer and examine the definition of radioactive iodine refractory disease and the
current systemic therapy … to specific targeted mutations in thyroid cancer. We also discuss novel …